無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

電位依存性カルシウムチャネルアルファ2/デルタ1サブユニット(CACNA2D1):パイプライン製品の分析

Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 368717
出版日 ページ情報 英文 52 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.36円で換算しております。
Back to Top
電位依存性カルシウムチャネルアルファ2/デルタ1サブユニット(CACNA2D1):パイプライン製品の分析 Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016
出版日: 2016年07月30日 ページ情報: 英文 52 Pages
概要

当レポートでは、電位依存性カルシウムチャネルアルファ2/デルタ1サブユニット(CACNA2D1)を標的とした治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

電位依存性カルシウムチャネルアルファ2/デルタ1サブユニット(CACNA2D1) 概要

治療薬の開発

  • 開発中の製品:開発段階別
  • 開発中の製品:治療領域別
  • 開発中の製品:症状別

パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

企業で開発中の製品

治療薬の評価

  • 単剤/併用治療薬の場合
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • 第一三共
  • Intellipharmaceutics International Inc.
  • Mapi Pharma Ltd.
  • Pfizer Inc.
  • Prismic Pharmaceuticals, Inc.
  • Yuhan Corporation

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

主なニュースおよびプレスリリース

付録

図表

目次
Product Code: GMDHC0432TDB

Summary:

Global Markets Direct's, 'Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Review, H2 2016', provides in depth analysis on Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted pipeline therapeutics.

The report provides comprehensive information on the Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
  • The report reviews Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) Overview
  • Therapeutics Development
    • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Stage of Development
    • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Therapy Area
    • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Indication
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Products under Development by Companies
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Companies Involved in Therapeutics Development
    • Daiichi Sankyo Company, Limited
    • Intellipharmaceutics International Inc.
    • Mapi Pharma Ltd.
    • Pfizer Inc.
    • Prismic Pharmaceuticals, Inc.
    • Yuhan Corporation
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Drug Profiles
    • (palmidrol + pregabalin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gabapentin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mirogabalin besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NVA-1309 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin IR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pregabalin XR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Dormant Projects
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Discontinued Products
  • Voltage Dependent Calcium Channel Subunit Alpha2/Delta1 (CACNA2D1) - Featured News & Press Releases
    • Jan 11, 2016: Pfizer Voluntarily Recalls Lyrica Capsules
    • Nov 25, 2015: Pfizer Reports Top-Line Results from a Phase 3 Study of LYRICA (pregabalin) Capsules CV in Adults with Post-Traumatic Peripheral Neuropathic Pain
    • Sep 10, 2015: Actavis Wins Patent Case Over Generic Lyrica
    • Mar 30, 2015: Intellipharmaceutics Submits and was Granted a Pre-IND Meeting Request with the US FDA for Its Regabatin XR (Pregabalin Extended Release Capsules) Drug Candidate
    • Mar 12, 2015: Pfizer Reports Top-Line Results From A Phase 4 Study Evaluating LYRICA Capsules CV As A Treatment For Adolescents With Fibromyalgia
    • Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin
    • Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia
    • Dec 10, 2014: Commonly Prescribed Drug for Lower Back Pain Not Effective
    • Nov 12, 2014: Pfizer to present data on LYRICA (pregabalin) capsules at ACR 2014 Annual Meeting
    • Nov 10, 2014: US Court Issues Final Order and Judgment Approving Class Action Settlement Related To Neurontin
    • Oct 22, 2014: Intellipharmaceutics Reports Positive Results from a Series of Phase I Clinical Trials of Regabatin XR (Pregabalin Extended-Release)
    • Aug 12, 2014: Pfizer Reports Top-line Results from Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy Lyrica Studies Conducted in China
    • Jun 02, 2014: Pfizer Agrees To Pay $325m To Settle Neurontin Case
    • Feb 21, 2014: Pfizer's Pregabalin Receives CHMP Positive Opinion
    • Dec 09, 2013: US Supreme Court Refuses To Hear Pfizer's Appeal On Marketing Of Neurontin
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Pipeline by Intellipharmaceutics International Inc., H2 2016
  • Pipeline by Mapi Pharma Ltd., H2 2016
  • Pipeline by Pfizer Inc., H2 2016
  • Pipeline by Prismic Pharmaceuticals, Inc., H2 2016
  • Pipeline by Yuhan Corporation, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top